DEA Administrator Compares Ketamine to Opioids
In a recent CBS News interview, DEA Administrator Anne Milgram compared the ketamine industry to the start of the opioid crisis, using Matthew Perry’s death as a sort of “canary in the coal mine” — essentially saying the number of people who get ketamine treatment will become addicted and turn to the streets to use ketamine will skyrocket. Read the full transcript here.
Do you work in the ketamine industry? We created the first newsletter just for you: Sign up here!
RELATED: Negative Sentiment Around Ketamine Clinics Increased 3500% After the Matthew Perry Arrests
Here’s an overview of her interview with Face the Nation:
Milgram contrasted this with ketamine, a promising treatment for depression and anxiety. It has shown potential to rapidly relieve symptoms in patients who do not respond to traditional antidepressants. However, ketamine’s use requires careful regulation to ensure safety.
Psychedelic AI is Here! Try out the beta version of HealingChat, HealingMaps AI chatbot that takes all our vetted content, clinics and retreats to answer all your questions in a safe environment. Try the beta version now!
Milgram pointed out that while ketamine offers hope, its administration must be monitored closely. Proper oversight is essential to balance benefits and risks. The focus should be on safe usage and adherence to medical standards.
The opioid crisis has strained healthcare resources, increasing the demand for addiction treatment and overdose interventions. Ketamine could help alleviate some of this burden by offering new treatment options for mental health issues. Milgram stressed the need for continued research and careful management.
RELATED: Is Ketamine Addictive? 5 Experts Weigh In
The DEA faces challenges in adapting to new treatments like ketamine while safeguarding public health. Milgram’s insights reflect the need for a balanced approach. Regulatory bodies must navigate these challenges to ensure effective and safe treatment options.
